

# Eleanor Mp Wilson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4720126/publications.pdf>

Version: 2024-02-01

41  
papers

1,215  
citations

567281

15  
h-index

377865

34  
g-index

41  
all docs

41  
docs citations

41  
times ranked

2076  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic Hepatitis B Infection. JAMA - Journal of the American Medical Association, 2018, 319, 1802.	7.4	473
2	Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers. Annals of Internal Medicine, 2017, 167, 311.	3.9	192
3	Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. Aids, 2014, 28, 831-840.	2.2	81
4	Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection. Annals of Internal Medicine, 2015, 163, 899-907.	3.9	53
5	APOBEC3 proteins can copackage and comutate HIV-1 genomes. Nucleic Acids Research, 2016, 44, 7848-7865.	14.5	41
6	Shortening the duration of therapy for chronic hepatitis C infection. The Lancet Gastroenterology and Hepatology, 2017, 2, 832-836.	8.1	35
7	Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. Clinical Infectious Diseases, 2015, 62, civ897.	5.8	31
8	Successful Treatment of a Recalcitrant Staphylococcus epidermidis Prosthetic Knee Infection with Intraoperative Bacteriophage Therapy. Pharmaceuticals, 2021, 14, 231.	3.8	28
9	Hepatitis C genotype 3 disease. Hepatology International, 2016, 10, 861-870.	4.2	26
10	Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. Hepatology International, 2017, 11, 161-170.	4.2	26
11	Augmentation of hepatitis C virus-specific immunity and sustained virologic response. Journal of Viral Hepatitis, 2017, 24, 742-749.	2.0	25
12	Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus. Hepatology Communications, 2018, 2, 1451-1466.	4.3	21
13	Pharmacokinetics of Anidulafungin in Pleural Fluid during the Treatment of a Patient with Candida Empyema. Antimicrobial Agents and Chemotherapy, 2011, 55, 2478-2480.	3.2	20
14	Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatology International, 2018, 12, 214-222.	4.2	20
15	A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY). Journal of Hepatology, 2019, 71, 498-504.	3.7	20
16	Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era. Journal of Clinical and Translational Hepatology, 2018, 6, 1-7.	1.4	18
17	Potential Use of Adjuvant Bacteriophage Therapy With Debridement, Antibiotics, and Implant Retention Surgery to Treat Chronic Prosthetic Joint Infections. Open Forum Infectious Diseases, 2021, 8, ofab277.	0.9	16
18	Observed transaminitis with a unique bacteriophage therapy protocol to treat recalcitrant Staphylococcal biofilm infections. Infection, 2022, 50, 281-283.	4.7	10

#	ARTICLE	IF	CITATIONS
19	Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 21-36.	3.0	9
20	Sofosbuvir/Velpatasvir/Voxilaprevir: A Highly Effective Option for Retreatment of Hepatitis C in Difficult-to-treat Patients. <i>Antiviral Therapy</i> , 2019, 24, 1-10.	1.0	8
21	Mechanisms of neuropathogenesis in HIV and HCV: similarities, differences, and unknowns. <i>Journal of NeuroVirology</i> , 2018, 24, 670-678.	2.1	7
22	Higher Levels of Fibrosis in a Cohort of Veterans with Chronic Viral Hepatitis are Associated with Extrahepatic Cancers. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 195-200.	0.9	7
23	HIV diagnosis and testing: what every healthcare professional can do (and why they should). <i>Oral Diseases</i> , 2013, 19, 431-439.	3.0	6
24	Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: Highly effective in a predominantly black male patient population. <i>Journal of Viral Hepatitis</i> , 2018, 25, 205-208.	2.0	6
25	Type I interferons and TGF- $\beta$ 2 cooperate to induce liver fibrosis during HIV-1 infection under antiretroviral therapy. <i>JCI Insight</i> , 2022, 7, .	5.0	6
26	Implementation of a unique hepatitis C care continuum model in Rwanda. <i>Journal of Public Health</i> , 2019, 41, e203-e208.	1.8	5
27	Virologic Response following Asunaprevir/Daclatasvir with or without Beclabuvir for Treatment of HCV Genotype 1 in Patients Co-Infected with HIV. <i>Journal of Hepatology</i> , 2016, 64, S760-S761.	3.7	4
28	Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection. <i>Transplantation Direct</i> , 2017, 3, e229.	1.6	4
29	Reconstitution of T follicular helper-humoral immune axis with elimination of hepatitis C virus. <i>Scientific Reports</i> , 2020, 10, 19924.	3.3	4
30	Sixty-year-old man with slowly expanding nodular plaque on the thigh. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 1083-1087.	1.2	3
31	Cytomegalovirus immune reconstitution inflammatory syndrome manifesting as sialadenitis in an HIV-infected patient. <i>Aids</i> , 2013, 27, 1833-1835.	2.2	3
32	Outcomes in Hepatitis C Positive Liver Transplantation: Timing of Direct-Acting Antiviral Treatment and Impact on Graft Fibrosis. <i>Viruses</i> , 2021, 13, 1831.	3.3	3
33	Hepatitis C genotype change after transplantation utilizing hepatitis C positive donor organs. <i>Transplant Infectious Disease</i> , 2018, 20, e12925.	1.7	2
34	High prevalence of gastrointestinal manifestations among Cytomegalovirus end-organ disease in the combination antiretroviral era. <i>Journal of Virus Eradication</i> , 2021, 7, 100052.	0.5	2
35	Can directly acting antiviral regimens against hepatitis C induce host immune responses?. <i>Future Virology</i> , 2018, 13, 147-150.	1.8	0
36	2194. Hepatitis B Care Cascade Within the VA Maryland Healthcare System. <i>Open Forum Infectious Diseases</i> , 2018, 5, S647-S648.	0.9	0

#	ARTICLE	IF	CITATIONS
37	1067. Interferon-free Hepatitis C Treatment Increases Surrogates of Cardiovascular Disease Risk in Black Veterans. <i>Open Forum Infectious Diseases</i> , 2020, 7, S562-S563.	0.9	0
38	1060. Evaluation of ALT at Sustained Virologic Response (SVR) in Patients with Treated Hepatitis C Virus (HCV) Infection. <i>Open Forum Infectious Diseases</i> , 2020, 7, S559-S559.	0.9	0
39	1057. CpG-adjuvanted Hepatitis B vaccination improves seroprotection rates in Veterans with HIV. <i>Open Forum Infectious Diseases</i> , 2020, 7, S558-S558.	0.9	0
40	851. Rate of Sexually Transmitted Infections and Engagement in HIV Pre-Exposure Prophylaxis at the Veterans Affairs Maryland Health System. <i>Open Forum Infectious Diseases</i> , 2021, 8, S515-S516.	0.9	0
41	Case Report and Review of Management of HIV/HCV Coinfection After Treatment Failure. <i>Current Treatment Options in Infectious Diseases</i> , 0, , .	1.9	0